Reina J; Iturbe A; Viana-Ramírez J; Sbert G; Carrasco J; Dueñas J

Abstract: Since 2023, a monoclonal antibody (nirsevimab) specifically directed against the preF form of RSV has been marketed in Spain. The impact of late immunization in the population <6 months="months" as="as" a="a" cause="cause" of="of" other="other" respiratory="respiratory" infections="infections" requiring="requiring" hospital="hospital" visit="visit" has="has" been="been" analyzed="analyzed">2025 doi: 10.1016/j.eimce.2024.10.002 https://pubmed.ncbi.nlm.nih.gov/39443235